Releases Details

MaxCyte, Inc.

("MaxCyte" or the "Company")

Notice of Half Year Results

Maryland, USA - 06 September 2016: MaxCyte (LSE: MXCT), an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, will be announcing its results for the half year ended 30 June 2016 on Tuesday, 27 September 2016.

Doug Doerfler, Chief Executive Officer, will host a presentation and live conference call for analysts at 11.00am BST on the day of the results at the offices of Panmure Gordon & Co., One New Change, London, EC4M 9AF.

For further information please contact:

About MaxCyte

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit http://www.maxcyte.com/